Formycon Pipeline Climbs To Six As It Adds Two Biosimilars

Partner Teva In Place For Ranibizumab Launch In UK And EU

 
• By Dean Rudge

Ahead of entering the planned commercialization stage for its first biosimilar product, German biotech Formycon has revealed a series of major announcements, including that it has beefed up its pipeline with an additional two new assets. Meanwhile, it expects to soon find a commercialization partner for its proposed Stelara biosimilar.

Arrows up (Sean Prior/Alamy Stock Photo)
2022 is set to be a landmark year for Formycon • Source: Shutterstock (Alamy Stock Photo)

German biosimilars developer Formycon AG has initiated development of an additional two undisclosed biosimilar projects, at the same time as it confirmed that its FYB201 biosimilar ranibizumab product Ongavia was still expected to be the first biosimilar Lucentis product marketed in Europe.

Amid a series of updates, Formycon has disclosed that for its two new biosimilar projects, FB208 and FYB209, “the reference molecules have been identified

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products